Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease

NCT03656627 is registered in ClinicalTrials.gov with Alliance Foundation Trials, LLC. as lead sponsor.

NCT NCT03656627
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03656627 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Activity, and Pharmacology of Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
Lead sponsor
Alliance Foundation Trials, LLC.
Phase
Phase 1
Overall status
Terminated
Start date
June 27, 2019
Completion date
March 18, 2021
Enrollment
7 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases, crohn disease, giant cell arteritis, multiple sclerosis, non-small cell lung cancer, polymyalgia rheumatica, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, ulcerative colitis